UW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA

Size: px
Start display at page:

Download "UW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA"

Transcription

1 Supplementary Table 1. Cases with deleterious germline mutations, somatic HR mutations, and somatic PTEN mutations. ID Site Stage Grade Histology Tumor Age Germline mutation(s) a Somatic HR mutation(s) a Somatic PTEN mutation a type at dx UW375 FT 2c 3 Serous Primary 53 BARD1 c.2148delca b UW54 Ovary 4 3 Serous Primary 53 BARD1 p.q715x, BRCA1 3600del11 UW338 Peritoneal 3c 3 Serous Primary 57 BRCA1 p.w1508x b ATM p.e2444x UW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2 UW382 Ovary 2c 3 Serous Primary 50 BRCA1 5382insC b CHEK2 c.1110del10 UWf4 Ovary 3c 3 Serous Primary 57 BRCA1 5382insC b PTEN c.857del7 UW424 Ovary 3c 3 Serous Primary 55 BRCA1 p.q780x b UW411 FT 3c 3 Serous Primary 55 BRCA1 1041delAGCinsT b UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA UW80 Ovary 3c 3 Serous Primary 41 BRCA1 187delAG UW416 Ovary 3c 3 Serous Primary 64 BRCA1 187delAG UW426 FT 3c 3 Serous Primary 63 BRCA1 187delAG UW50 Ovary 3c 3 Serous Primary 48 BRCA1 2190delA UW32 Ovary 3c 3 Serous Primary 40 BRCA1 2576delC UW65 Ovary 3c 3 Serous Primary 57 BRCA1 2594delC

2 UW40 Ovary 4 3 Serous Primary 54 BRCA1 2594delC UW100 Ovary 3c 3 Serous Primary 44 BRCA1 2798delGAAA b UW457 Ovary 3c 3 Serous Primary 50 BRCA1 2800delAA UWf161 Ovary 3c 3 Serous Primary 55 BRCA1 3059delA UW440 Ovary 3c 3 Serous Primary 50 BRCA1 3171insTGAGA UW317 Ovary 3c 3 Serous Recurrent 47 BRCA1 3171insTGAGA b UWf100 Ovary 4 3 Serous Primary 58 BRCA1 3995delT b UW238 Ovary 4 3 Serous Primary 51 BRCA1 4160delAG b UW210 Ovary 3c 3 Serous Primary 46 BRCA1 4239delAG b UW218 Ovary 4 3 Serous Primary 55 BRCA1 4603G>T splice b UW129 Ovary 4 3 Serous Primary 69 BRCA1 5301delA b UW297 Peritoneal 3c 3 Serous Primary 65 BRCA1 5382insC b UW248 Ovary 3c 3 Serous Primary 57 BRCA1 5382insC b UW36 Ovary 3c 3 Serous Primary 41 BRCA1 5396(+1)G>A splice UW357 Ovary 3c 3 Serous Primary 44 BRCA1 917delTT b UW325 Ovary 3c 3 Serous Primary 49 BRCA1 943ins10 b UW387 Ovary 3c 3 Serous Primary 52 BRCA1 del exon b

3 UW291 FT 3c 3 Serous Primary 61 BRCA1 dup exon 13 b UW208 FT 3c 3 Serous Primary 55 BRCA1 p.e1250x UW437 Ovary NA 3 Serous Recurrent 60 BRCA1 p.e1250x UW245 Ovary 3c 3 Serous Primary 49 BRCA1 p.m1775r b UW406 Ovary 3c 3 Serous Primary 47 BRCA1 p.m1i b UW454 Ovary 3c 3 Serous Primary 46 BRCA1 p.g1706e UW342 Ovary 3c 3 Poorlydifferentiated Primary 70 BRCA1 p.v1736a UW370 Ovary NA 3 Serous Primary 42 BRCA1 p.q1200x b UW305 Ovary 3c 3 Serous Primary 51 BRCA1 p.r1203x UW43 Ovary 3c 3 Serous Primary 49 BRCA1 p.w1782x UW266 Peritoneal 3c 3 Serous Primary 63 BRCA1 p.w321x b UW165 Ovary 3c 3 Endometrioid Primary 40 BRCA1 187delAG UWf77 Ovary 3a 3 Carcinosarcoma Primary 52 BRCA1 2080delA UW394 FT 1a 3 Poorlydifferentiated UW141 FT 3c 3 Poorlydifferentiated UW224 Ovary 3c 3 Poorlydifferentiated UW331 Ovary 4 3 Poorlydifferentiated Recurrent 39 BRCA1 3109insAA Primary 69 BRCA1 4154delA Primary 54 BRCA1 del exon 14 b Primary 44 BRCA1 del exon 3 b

4 UW356 FT 1c 3 Poorlydifferentiated Recurrent 61 BRCA1 p.c61g UW323 Ovary 3c 1 Serous Primary 45 BRCA2 1158delAT b UW145 Ovary 3c 3 Serous Primary 63 BRCA2 2116insA b UWf150 Ovary Na 3 Serous Primary 64 BRCA2 4075delGT UW174 Ovary 4 3 Serous Recurrent 63 BRCA2 5578delAA UW130 Ovary 3c 3 Serous Primary 53 BRCA2 6174delT b UW101 Ovary 3c 3 Serous Primary 58 BRCA2 6503delTT b UW70 Ovary 3c 3 Serous Primary 56 BRCA2 6672insT b UW78 Ovary 3c 3 Serous Primary 51 BRCA2 7297delCT UW292 Ovary 3c 3 Serous Primary 48 BRCA2 745(-2)A>G splice b UW137 Peritoneal 3c 3 Serous Primary 69 BRCA2 7846(-1)G>A splice b UW352 Ovary 3c 3 Serous Primary 49 BRCA2 p.c3097x b UW404 FT 3c 3 Serous Primary 56 BRCA2 p.e1415x b PTEN del exon 2 UW377 FT 3c 3 Serous Primary 62 BRCA2 p.k2013x b UW157 Ovary 3c 3 Poorlydifferentiated Primary 70 BRCA2 1417insTTAG b UWf2 Ovary 3c 3 Endometrioid Primary 49 BRCA2 3034delAAAC UW200 Ovary 3b 3 Poorlydifferentiated Primary 49 BRCA2 4689delAC b

5 UW340 Ovary 3c 3 Poorlydifferentiated Primary 56 BRCA2 p.y1655x b UW236 Ovary 3c 3 Serous Primary 66 BRIP1 2108delAinsTCC b UW184 Peritoneal 4 3 Poorlydifferentiated Primary 51 BRIP1 c.2010inst b UW255 Ovary 3c 3 Serous Primary 50 BRIP1 c del (part of exon 18) b UW383 Ovary 1c 1 Endometrioid Primary 47 BRIP1 p.r798x b, MSH6 p.r1035x b UW88 Ovary 3c 3 Serous Recurrent 42 CHEK1 p.q346x PTEN c.955delactt UW16 Ovary 3c 3 Serous Primary 69 CHEK2 c.1100delc BRCA2 7656delA UW186 Ovary 3c 3 Serous Primary 45 CHEK2 p.s400f b UW400 Ovary 1a 3 Clear cell Recurrent 68 CHEK2 p.s428f UW96 Ovary 3c 3 Malignant Primary 73 FAM175A c.1106insg Brenner's UW435 Ovary 1c 3 Serous Primary 54 FAM175A c.1106insg UW350 Ovary 4 3 Serous Primary 64 NBN c.1142delc b UWf103 Ovary 3b 3 Serous Primary 51 PALB2 c.1050delaaca b UW196 Peritoneal 3c 3 Serous Primary 58 PALB2 c.757delag b UW250 Ovary 2c 3 Poorlydifferentiated Primary 51 RAD51C c.224insa b UW407 Peritoneal 4 3 Carcinosarcoma Primary 70 RAD51C c A>G splice b UW419 Ovary 4 3 Serous Primary 47 RAD51C p.r193x

6 UW422 Ovary 3c 3 Serous Primary 75 RAD51D c.131_144+24del38 c UW132 Ovary 1c 3 Endometrioid Primary 34 RAD51D c.580dela c PTEN c.389delg UW181 Ovary 4 3 Poorlydifferentiated Primary 43 RAD51D p.r232x c UW468 Ovary 3c 3 Serous Primary 74 RAD51D p.y47x UW77 Ovary 3c 3 Serous Primary 82 BUB1B c.3086delg UW119 Ovary 3c 3 Serous Primary 44 MSH2 p.r929x BRCA1 3721delG UW33 Ovary 3c 2 Serous Primary 64 TP53 p.y220c UW277 Ovary 1c 2 Endometrioid Primary 64 TP53 p.r175c b UW330 FT 3c 3 Serous Primary 64 TP53 p.r175h mosaic b UW381 Ovary NA 1 Endometrioid Recurrent 67 ATM c.3284(+1)g>c splice UW408 Ovary 3c 3 Clear cell Primary 44 ATM c.5441delt PTEN c.678delc UW358 Ovary 3c 3 Clear cell Primary 29 BRCA1 1135insA, BRIP1 c.3260insa, MRE11A c.1196instt PTEN c.968insa UW109 Ovary 4 3 Poorlydifferentiated Primary 70 BRCA1 p.e1536x UW190 Ovary 3c 3 Serous Primary 76 BRCA1 2913delG UW124 Ovary 3c 3 Carcinosarcoma Primary 53 BRCA1 3481delA UW256 Ovary 3c 3 Serous Primary 72 BRCA1 3712delT

7 UW178 Ovary 1c 3 Poorlydifferentiated Primary 69 BRCA1 5397(-2)A>T splice UW23 Ovary 3c 2 Serous Primary 47 BRCA1 5451(+2)T>C splice UW133 Ovary 4 3 Serous Primary 39 BRCA1 560(+2)T>C splice UW156 Ovary 3c 3 Poorlydifferentiated Primary 53 BRCA1 dup exon UW362 Ovary 3c 3 Serous Primary 74 BRCA1 dup exon UW341 Ovary 1a 2 Endometrioid Primary 65 BRCA1 dup exon UW58 Ovary 3c 3 Serous Primary 43 BRCA1 p.e1410x UW7 Ovary 3b 3 Serous Primary 52 BRCA1 p.e670x UW201 Ovary 3c 3 Poorlydifferentiated Primary 58 BRCA1 p.e879x UW94 Peritoneal 3c 3 Poorlydifferentiated Primary 60 BRCA1 p.q172x UWf94 Ovary 3c 3 Serous Primary 62 BRCA1 p.s1457x UW95 Ovary 3c 3 Poorlydifferentiated Primary 62 BRCA2 5788delGT UW276 Ovary 3c 3 Serous Primary 62 BRCA2 6671delC UW131 Ovary 1a 2 Endometrioid Primary 80 BRCA2 p.r2494x UWf14 Ovary 1a 3 Clear cell Primary 38 BRCA2 p.s368x UW24 Ovary 3c 3 Serous Primary 67 BRCA2 p.y2854x UW243 Ovary 3c 3 Serous Primary 48 BRIP1 del exon 12-14

8 UW420 Ovary 1a 3 Clear cell Primary 50 CHEK2 del exon 1-7 UW425 FT 3c 3 Serous Primary 51 CHEK2 del exon 3-10 UW177 Ovary 3a 3 Serous Primary 64 Rad51C del exon 1-3 UW410 Ovary 3c 3 Carcinosarcoma Primary 64 PTEN c.237insc UW2 Ovary 4 3 Serous Primary 71 PTEN c.389delg UW93 Ovary 2c 3 Endometrioid Primary 66 PTEN c.801(+1)g>c splice UW403 Ovary 1c 2 Endometrioid Primary 58 PTEN c.955delactt UW386 Ovary 1c 3 Serous Primary 85 PTEN del exon 6-9 UW379 FT 4 3 Serous Primary 68 PTEN del ex 6 UW198 Ovary 3c 3 Poorlydifferentiated Primary 70 PTEN del exon 1 UW265 Ovary 3c 3 Serous Primary 82 PTEN del exon 1-3 UW82 Ovary 3c 2 Serous Primary 56 PTEN del exon 2-9 UW286 Ovary 4 3 Serous Primary 60 PTEN del exon 6-8 UW431 Ovary 4 3 Serous Primary 53 PTEN del exon 9 UW49 Ovary 1c 3 Mixed (endometrioid 90% and clear cell 10%) UW211 Peritoneal 3c 3 Poorlydifferentiated Primary 58 PTEN whole gene deletion (homozygous) Primary 68 PTEN whole gene deletion (homozygous)

9 UW309 Ovary 4 3 Poorlydifferentiated Primary 50 PTEN dup exon 3-5 UW42 Ovary 1a 3 Clear cell Primary 52 PTEN p.r233x UW61 Ovary 4 2 Serous Primary 47 PTEN p.s59x FT=fallopian tube. NA= not available/unknown. Dx= diagnosis. = not otherwise specified a Accession numbers are as follows: ATM, NM_000051; BARD1, NM_000465; BRIP1, NM_032043; BUB1B, NM_001211; CHEK1, NM_ ; CHEK2, NM_007194; FAM175A, NM_139076; MRE11A, NM_005591; MSH2, NM_000251; MSH6, NM_000179; NBN, NM_002485; PALB2, NM_024675; PTEN, NM_000314; RAD51C, NM_058216; RAD51D, NM_002878; TP53, NM_ BRCA1 and BRCA2 mutations were annotated using BIC designation ( reference sequences: BRCA1 GenBank U14680; BRCA2 GenBank U43746); all other mutations were annotated using HGVS nomenclature. b Previously reported by Walsh et al [1] c Previously reported by Wickramanyake et al [2] [1] Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011;108: [2] Wickramanyake A., Bernier G., Pennil C., Casadei S., Agnew K. J., Stray S. M., et al. Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Gynecol Oncol 2012;127:

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM Supplementary Data Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM cohort. Supplementary Table e2. Specificity, sensitivity and unadjusted ORs for glioma in participants

More information

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome

More information

Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain

Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?

More information

Genetic Testing for BRCA1 and BRCA2 Genes

Genetic Testing for BRCA1 and BRCA2 Genes Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling

More information

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome

More information

Genetic Testing for BRCA1 and BRCA2 Genes

Genetic Testing for BRCA1 and BRCA2 Genes Genetic Testing f BRCA1 and BRCA2 Genes MP9478 Covered Service: Pri Authization Required: Additional Infmation: Yes when meets criteria below Yes--as shown below Pre and post-test genetic counseling is

More information

BRCAplus. genetic testing for hereditary breast cancer

BRCAplus. genetic testing for hereditary breast cancer BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial

More information

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017 Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA

More information

Use of panel tests in place of single gene tests in the cancer genetics clinic

Use of panel tests in place of single gene tests in the cancer genetics clinic Clin Genet 2015: 88: 278 282 Printed in Singapore. All rights reserved CLINICAL GENETICS doi: 10.1111/cge.12488 Short Report se of panel tests in place of single gene tests in the cancer genetics clinic

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth

More information

MSI positive MSI negative

MSI positive MSI negative Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden

More information

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive

More information

Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep

Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Tom Walsh, PhD Division of Medical Genetics University of Washington Next generation sequencing Sanger sequencing gold

More information

Supplementary Figure 1

Supplementary Figure 1 Supplementary Figure 1 A B HEC1A PTEN +/+ HEC1A PTEN -/- 16 HEC1A PTEN -/- 22 PTEN RAD51 % Cells with RAD51 foci 40 -IR +IR 30 20 10 * *! TUBULIN 0 HEC1A PTEN+/+ HEC1A PTEN-/- 16 HEC1A PTEN-/- 22 C D 1.0

More information

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,

More information

Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes

Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University

More information

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins. WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE

More information

Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues

Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program Risks Related to Breast Cancer Advancing Age! Early Menarche!

More information

Germline Testing for Hereditary Cancer with Multigene Panel

Germline Testing for Hereditary Cancer with Multigene Panel Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with

More information

Managing Moderate Penetrance

Managing Moderate Penetrance Managing Moderate Penetrance Thomas Slavin, MD, FACMG Assistant Clinical Professor, Department of Medical Oncology, Division of Clinical Cancer Genetics Program Member, Cancer Control and Population Sciences

More information

Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático

Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth

More information

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins. WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE

More information

Advanced Ovarian Carcinoma

Advanced Ovarian Carcinoma Advanced Ovarian Carcinoma What is our standard of care? IV carbo/taxol IP platinum/taxane (what regimen?) IV carbo/taxol/bevacizumab + 12 months of Bev IV carbo + dose dense taxol Controversy between

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Pearlman R, Frankel WL, Swanson B, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol.

More information

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective

Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families

More information

Germline Genetic Testing for Breast Cancer Risk

Germline Genetic Testing for Breast Cancer Risk Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)

More information

OvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer

OvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer patient guide OvaNext genetic testing for hereditary breast, ovarian, and uterine cancer Because knowing your risk can mean early detection and prevention About half of the women diagnosed with uterine

More information

Cancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2

Cancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2 AWARD NUMBER: W81XWH-15-1-0084 TITLE: Cancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2 PRINCIPAL INVESTIGATOR: Elizabeth Swisher CONTRACTING

More information

Learn your genetic risk for the most common hereditary cancers.

Learn your genetic risk for the most common hereditary cancers. Learn your genetic risk for the most common hereditary cancers. color.com Color analyzes 30 genes including BRCA1 and BRCA2 to help women and men understand their risk for the most common hereditary cancers,

More information

The Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine

The Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine The Value of Panel Testing in Inherited Breast Cancer Risk Assessment Rodney J. Scott Division of Molecular Medicine Mutation Detection Next Generation DNA sequencing has revolutionised mutation detection

More information

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast

More information

Hereditary Cancer Products

Hereditary Cancer Products Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed

More information

Medical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011

Medical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011 Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective

More information

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime types

More information

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You? A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is

More information

The Next Generation of Hereditary Cancer Testing

The Next Generation of Hereditary Cancer Testing The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,

More information

GENETIC VARIATION OF THE BRCA1 AND BRCA2 GENES IN MACEDONIAN PATIENTS

GENETIC VARIATION OF THE BRCA1 AND BRCA2 GENES IN MACEDONIAN PATIENTS BJMG Supplement 15 (2012) 81-85 10.2478/v10034 012 0025 8 Proceedings of the MACPROGEN Final Conference held at Ohrid, Republic of Macedonia, March 29-April 1 2012 GENETIC VARIATION OF THE BRCA1 AND BRCA2

More information

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents

More information

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention Know the Basics Breast cancer is the most common cancer in women

More information

Hereditary Breast and Ovarian Cancers: Risk Management Recommendations. Objectives

Hereditary Breast and Ovarian Cancers: Risk Management Recommendations. Objectives Hereditary Breast and Ovarian Cancers: Risk Management Recommendations Tuya Pal, MD Moffitt Cancer Center Objectives 1 Identify genes associated with Hereditary Breast/Ovarian Cancer, including new and

More information

BRCA Mutations and Outcome in Epithelial Ovarian Cancer: Experience in Ethnically Diverse Groups

BRCA Mutations and Outcome in Epithelial Ovarian Cancer: Experience in Ethnically Diverse Groups BRCA Mutations and Outcome in Epithelial Ovarian Cancer: Experience in Ethnically Diverse Groups Tamar Safra, MD, Barliz Waissengrin, MD, Lucia Borgato, MD, Moshe Leshno, MD, Elsa Reich, MD, Julia Smith,

More information

TumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in

TumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in SAMPLE REPORT Ordered By Contact ID:1251298 Example, Doctor, MD MOCKORG44 (10829) 123 Somewhere LaneSuite 4 Heaven NV 78872 US Ph:123-123-1234 Fx:123-123-1223 Org ID:8141 Normal Specimen Accession #: 00-086947

More information

Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD

Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies

More information

The Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno

The Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno The Role of Genetics in Ovarian Cancer Screening Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno How Much Breast and Ovarian Cancer Is Hereditary? 15%-20% 5%-10% Breast Cancer

More information

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome Hereditary Ovarian and Breast Cancer Syndrome C. Blake Gilks, MD Dept of Pathology Vancouver General Hospital University of British Columbia Blake.gilks@vch.ca The USCAP requires that anyone in a position

More information

Policy and Procedure. Department: Utilization Management. SNP, CHP, MetroPlus Gold, Goldcare I&II, Market Plus, Essential, HARP

Policy and Procedure. Department: Utilization Management. SNP, CHP, MetroPlus Gold, Goldcare I&II, Market Plus, Essential, HARP Retired Date: Page 1 of 9 1. POLICY DESCRIPTION: BRCA 1&2 Genetic Testing 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy, Claim

More information

Multigene Panel Testing for Hereditary Cancer Risk

Multigene Panel Testing for Hereditary Cancer Risk Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline

More information

Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues

Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program Timeline of Important Events in DNA Patenting (Top) and

More information

Disclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%

Disclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47% Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and

More information

Why Test for Hereditary Cancer in Preventive Care?

Why Test for Hereditary Cancer in Preventive Care? Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in

More information

A guide to genetic testing for hereditary cancers

A guide to genetic testing for hereditary cancers Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions

More information

The Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh

The Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and

More information

Genetic Testing for Hereditary Cancer Susceptibility

Genetic Testing for Hereditary Cancer Susceptibility Clinical Appropriateness Guidelines Genetic Testing for Hereditary Cancer Susceptibility EFFECTIVE OCTOBER 7, 2018 Appropriate.Safe.Affordable 2018 AIM Specialty Health 2064-1018 Table of Contents Scope...

More information

CASE STUDY. Mutation-Specific Testing: Eligibility for PARP Inhibitor Therapy Established. Introduction. Patient Profile.

CASE STUDY. Mutation-Specific Testing: Eligibility for PARP Inhibitor Therapy Established. Introduction. Patient Profile. CASE STUDY Mutation-Specific Testing: Eligibility for PARP Introduction Genetic testing is an emergent diagnostic technique that can provide specific and actionable inputs to the management of cancer therapy.

More information

Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center

Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Following this presentation you will be able to: Identify cancer survivors in your practice who might benefit from genetic counseling

More information

Supplementary Table 2. Identified causative mutations and/or mutation candidates.

Supplementary Table 2. Identified causative mutations and/or mutation candidates. Supplementary Table 2. Identified causative mutations and/or mutation candidates. Nonsense mutations base change aa change Average depth Result of next generation in 432 patient Hereditary form of the

More information

The Role of genetic Testing for Inherited Prostate Cancer Risk

The Role of genetic Testing for Inherited Prostate Cancer Risk FOIU July 2018 The Role of genetic Testing for Inherited Prostate Cancer Risk Leonard G. Gomella, MD Chairman, Department of Urology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,

More information

Genetic testing and pancreatic disease

Genetic testing and pancreatic disease Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,

More information

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP Frequency Domain Mammals a 3 S/P b Mammals a 3 S/P b

More information

Myriad Financial Assistance Program (MFAP)

Myriad Financial Assistance Program (MFAP) Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.

More information

Are you at risk of Hereditary Cancer? Your Guide to the Answers

Are you at risk of Hereditary Cancer? Your Guide to the Answers Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,

More information

Cystic fibrosis carrier screening in a North American population

Cystic fibrosis carrier screening in a North American population American College of Medical Genetics and Genomics Original Research Article Cystic fibrosis carrier screening in a North American population Val V. Zvereff, MD,PhD 1, Hawazin Faruki, DrPh 1, Marcia Edwards,

More information

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing

More information

Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients

Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients Breast Cancer Res Treat (207) 63:383 390 DOI 0.007/s0549-07-48-0 BRIEF REPORT Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients Beth

More information

Breast and ovarian cancer risk assessment using multigene panel tests Prof Antonis Antoniou

Breast and ovarian cancer risk assessment using multigene panel tests Prof Antonis Antoniou Breast and ovarian cancer risk assessment using multigene panel tests Prof Antonis Antoniou Department of Public Health and Primary Care University of Cambridge, U.K. Cancer risk prediction in the era

More information

Hereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com

Hereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic

More information

Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues

Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program Risk Factors for Breast Cancer Aging Family history Early

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose)

More information

CASE STUDY. Germline Cancer Testing in A Proband: Extension of Benefits to Unaffected Family Members. Introduction. Patient Profile.

CASE STUDY. Germline Cancer Testing in A Proband: Extension of Benefits to Unaffected Family Members. Introduction. Patient Profile. CASE STUDY Germline Cancer Testing in A Proband: Extension of Benefits to Unaffected Family Members Introduction Most cancers are caused by genetic damage resulting from random mutations and exposure to

More information

Enabling Personalized

Enabling Personalized Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development

More information

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime

More information

A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer

A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer YUTAKA AMEMIYA 1,2, STEPHANIE BACOPULOS 2, MOHAMED AL-SHAWARBY 3, DALAL

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Wells JM, Farris RF, Gosdin TA, et al. Pulmonary

More information

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Hereditary cancer and you Approximately 5% to 10% of all cancers develop because a person inherited a genetic

More information

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a

More information

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer Supplementary Materials Supplementary

More information

Predictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD

Predictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex

More information

Genetic testing for hereditary cancer

Genetic testing for hereditary cancer Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of

More information

Issues arising from UKNEQAS schemes. Ottie O Brien, Northern Genetics Service, Newcastle, UK 15 th May 2014

Issues arising from UKNEQAS schemes. Ottie O Brien, Northern Genetics Service, Newcastle, UK 15 th May 2014 Issues arising from UKNEQAS schemes Ottie O Brien, Northern Genetics Service, Newcastle, UK 15 th May 2014 2013 schemes There was great variation in the way HGVS nomenclature was applied Scheme would like

More information

Genetic Risk Assessment for Cancer

Genetic Risk Assessment for Cancer Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role

More information

Proactive Patient Paves the Way for Genetic Testing of Eight Family Members

Proactive Patient Paves the Way for Genetic Testing of Eight Family Members CASE STUDY Proactive Patient Paves the Way for Genetic Testing of Eight Family Members Quick Summary Samar Mohite * was diagnosed with colon adenocarcinoma at the age of 49 years. Genetic counselling was

More information

PROVIDER POLICIES & PROCEDURES

PROVIDER POLICIES & PROCEDURES PROVIDER POLICIES & PROCEDURES GENETIC CANCER SUSCEPTIBILITY PANELS USING NEXT GENERATION SEQUENCING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program

More information

DNA Genetic Cancer Risk Test. Test Report

DNA Genetic Cancer Risk Test. Test Report Test Report CONTENTS SECTION 1 1-1. Customer Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Cancers / Tumors Tested SECTION 2 2-1. About the Test 2-2. References 1 CL0040-1_B

More information

CASE STUDY. Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk. Introduction.

CASE STUDY. Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk. Introduction. CASE STUDY Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk Introduction Germline cancer risk assessment tests are well-prescribed tests from Strand Life

More information

Raccomandazioni del Genetista. Dott.ssa Raffaella Casolino - Oncologia Negrar

Raccomandazioni del Genetista. Dott.ssa Raffaella Casolino - Oncologia Negrar Raccomandazioni del Genetista Dott.ssa Raffaella Casolino - Oncologia Negrar Genetic Test and Ovarian Cancer International Recomandations for BRCA Genetic Test NCCN (National Comprehensive Cancer Network):

More information

Modelling cancer risk predictions:clinical practice perspective.

Modelling cancer risk predictions:clinical practice perspective. Modelling cancer risk predictions:clinical practice perspective. Judith Balmaña, MD, PhD Familial Cancer Program Medical Oncology Department Hospital Vall d Hebron, VHIO Barcelona, Spain It is very difficult

More information

GENETIC TESTING FOR HEREDITARY CANCER

GENETIC TESTING FOR HEREDITARY CANCER UnitedHealthcare Oxford Clinical Policy GENETIC TESTING FOR HEREDITARY CANCER Policy Number: DIAGNOSTIC 004.27 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS

More information

Nature Genetics: doi: /ng Supplementary Figure 1. TCGA data set on HNSCCs reanalyzed in this study.

Nature Genetics: doi: /ng Supplementary Figure 1. TCGA data set on HNSCCs reanalyzed in this study. Supplementary Figure 1 TCGA data set on HNSCCs reanalyzed in this study. Summary of the TCGA dataset on HNSCCs re-analyzed in this study and the respective numbers of samples available within each. Supplementary

More information

Understanding Your Positive Result. A guide to understanding your risk and taking action

Understanding Your Positive Result. A guide to understanding your risk and taking action Understanding Your Positive Result A guide to understanding your risk and taking action 2017 Myriad Genetics, Inc. 320 Wakara Way, Salt Lake City, Utah 84108 PH: 1-800-469-7423 FX: 801-584-3615 1 PART

More information

Clinical Policy Title: Genetic testing for breast and ovarian cancer

Clinical Policy Title: Genetic testing for breast and ovarian cancer Clinical Policy Title: Genetic testing for breast and ovarian cancer Clinical Policy Number: 02.01.02 Effective Date: September 1, 2013 Initial Review Date: March 21, 2013 Most Recent Review Date: May

More information

Genetic Testing: who, what, why?

Genetic Testing: who, what, why? Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk

More information

Genetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania

Genetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART

More information

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 GENETEST REVIEW Genetics in Medicine Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 Nancie Petrucelli, MS, CGC 1, Mary B. Daly, MD, PhD 2, and Gerald L. Feldman, MD, PhD 3 TABLE

More information

HEREDITY & CANCER: Breast cancer as a model

HEREDITY & CANCER: Breast cancer as a model HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic

More information

Simple But Complicated: Genetic Testing in Hereditary Gynecologic Cancers

Simple But Complicated: Genetic Testing in Hereditary Gynecologic Cancers Simple But Complicated: Genetic Testing in Hereditary Gynecologic Cancers Robert Resta, MS, Licensed/Certified Genetic Counselor, Hereditary Cancer Clinic, Swedish Medical Center, Seattle, WA Nota Bene

More information

Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results

Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results Breast Cancer Res Treat (2017) 161:575 586 DOI 10.1007/s10549-016-4085-4 EPIDEMIOLOGY Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results Mary Pritzlaff 1 Pia Summerour

More information